Latest Tipranavir Stories
TITUSVILLE, N.J., Jan. 3, 2011 /PRNewswire/ -- The U.S.
TITUSVILLE, N.J., Dec. 13, 2010 /PRNewswire/ -- Tibotec Therapeutics, a division of Centocor Ortho Biotech Products, L.P., announced today that the U.S.
ABBOTT PARK, Ill., Feb. 11 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has granted approval of a new tablet formulation of the company's antiretroviral medication Norvir Â® (ritonavir).
BRIDGEWATER, N.J., Nov. 25 /PRNewswire/ -- The FDA granted traditional approval for INTELENCEÂ® (etravirine) tablets, a non-nucleoside reverse transcriptase inhibitor (NNRTI).
BRIDGEWATER, N.J., Feb. 5 /PRNewswire/ -- Tibotec, Inc. today announced it has submitted an application to the U.S. Food and Drug Administration (FDA) seeking traditional approval for INTELENCE(TM) (etravirine) tablets, a non-nucleoside reverse transcriptase inhibitor (NNRTI).
WASHINGTON, Oct. 26 /PRNewswire/ -- Sequoia Pharmaceuticals presented positive results today from two studies on SPI-256, a novel investigational HIV protease inhibitor (PI).
BRIDGEWATER, N.J., Oct.
Boehringer Ingelheim Pharmaceuticals has announced that the FDA has granted approval for Aptivus capsules/oral solution with dosing information for treatment-experienced pediatric patients between the ages of 2-18 infected with HIV-1.
RIDGEFIELD, Conn., June 24 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S.